Conflict of Interest Policy Limits Industry Control Over Studies, Publication
This article was originally published in The Tan Sheet
Executive Summary
Study sponsors will have a limited time to review manuscripts in order to devise marketing plans for the studied drug before they are published, a revised policy on conflicts of interest released by various major medical journals states.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning